1. PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis
   Subbroto Kumar Saha et al, 2020, Cancer Gene Therapy CrossRef
2. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
   null Jomrich et al, 2019, Cells CrossRef
3. Cancer stem cells in esophageal squamous cell carcinoma
   Guorui Sun et al, 2022, Pathology - Research and Practice CrossRef
4. The clinicopathological significance of CD133 and Sox2 in astrocytic glioma
   Aziza E. Abdelrahman et al, 2018, Cancer Biomarkers CrossRef
5. Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies
   Miguel Pereira-Silva et al, 2020, European Journal of Pharmaceutics and Biopharmaceutics CrossRef
6. Cancer stem cells with increased metastatic potential as a therapeutic target for esophageal cancer
   D. Wang et al, 2017, Seminars in Cancer Biology CrossRef
7. Cancer stem cells in esophageal cancer and response to therapy
   Kazuto Harada et al, 2018, Cancer CrossRef
8. Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer
   Chenghui Zhou et al, 2020, Cells CrossRef
9. CD133 in brain tumor: the prognostic factor
   Bin Li et al, 2017, Oncotarget CrossRef
10. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer
    Fan Li et al, 2019, Clinical Cancer Research CrossRef
11. MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis
    Jin‐Dan Kai et al, 2022, Cell Biology International CrossRef
12. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients
    Yao-Li Chen et al, 2017, BMC Cancer CrossRef